European psychiatry : the journal of the Association of European Psychiatrists
June 10, 2026
Riccardo Guglielmo, Miriam Olivola, Alberto Inuggi et al.
Esketamine has demonstrated efficacy in treatment-resistant depression (TRD), but medium-term real-world functional outcomes remain understudied. This study described 6-month depressive symptoms and functional trajectories during routine esketamine treatment, focusing on functional outcomes and remission correlates. In this prospective multicenter study, 60 patients with TRD initiating...
European psychiatry : the journal of the Association of European Psychiatrists
February 13, 2026
Haining Ma, Huaigui Liu, Wenwei Zhang et al.
Considerable effort has been devoted to investigate the neuroimaging correlates and predictors of antidepressant response to ketamine, yet inconsistency in the location and nature of the regional brain effects makes it difficult to unify this research. Despite the revolutionary notion that psychiatric therapeutics show network-level brain representations, investigations into network...
European psychiatry : the journal of the Association of European Psychiatrists
October 14, 2025
Andreas Reif, Bernhard T Baune, Jozefien Buyze et al.
Clinical response and remission may not fully reflect patient priorities in treatment-resistant depression (TRD). Health-related quality-of-life (HRQoL) outcomes should be assessed to comprehensively capture treatment benefits. ESCAPE-TRD (NCT04338321) was a 32-week randomized, phase IIIb trial comparing esketamine nasal spray (NS) versus quetiapine extended release (XR), both alongside an...
European psychiatry : the journal of the Association of European Psychiatrists
August 26, 2025
Ismaël Conejero, Raquel Alvarez García, Alejandro Porras-Segovia et al.
2 citations
Esketamine has been shown to produce a major antidepressant response in patients with treatment-resistant depression (TRD). We evaluated the factors associated with achieving remission in these individuals. The study was carried out across four psychiatry departments in Madrid, Spain. Patients aged over 18 years were included if they received esketamine as an augmentation treatment for TRD....
European psychiatry : the journal of the Association of European Psychiatrists
February 5, 2025
Shokouh Arjmand, Mats B Lindström, Carl M Sellgren et al.
1 citation
The dissociative effects of ketamine and psychedelics might be associated with their rapid antidepressant properties, raising questions about whether these effects are necessary for their therapeutic action. Additionally, the distinct dissociative experiences often reported by patients in clinical trials may reveal whether they receive an active treatment or a placebo, potentially introducing...
European psychiatry : the journal of the Association of European Psychiatrists
April 4, 2024
Haiyan Liu, Chengyu Wang, Xiaofeng Lan et al.
7 citations
Amygdala subregion-based network dysfunction has been determined to be centrally implicated in major depressive disorder (MDD). Little is known about whether ketamine modulates amygdala subarea-related networks. We aimed to investigate the relationships between changes in the resting-state functional connectivity (RSFC) of amygdala subregions and ketamine treatment and to identify important...
European psychiatry : the journal of the Association of European Psychiatrists
October 2010
B Weber, Françoise Jermann, M Gex-Fabry et al.
The present open study investigates the feasibility of Mindfulness-based cognitive therapy (MBCT) in groups solely composed of bipolar patients of various subtypes. MBCT has been mostly evaluated with remitted unipolar depressed patients and little is known about this treatment in bipolar disorder. Bipolar outpatients (type I, II and NOS) were included and evaluated for depressive and hypomanic...
European psychiatry : the journal of the Association of European Psychiatrists
November 1, 2007
Ludwig Grepmair, Ferdinand Mitterlehner, Thomas Loew et al.
This study examined whether the promotion of mindfulness in psychotherapists in training can influence the treatment results of their patients. The therapeutic course and treatment results of 196 inpatients, who were treated during a nine week period by nine psychotherapists in training, were compared: in the first phase of the study, the treatment group without (CG, historical control group,...
European psychiatry : the journal of the Association of European Psychiatrists
December 1, 1998
Euphrosyne Gouzoulis‐mayfrank, Elmar Habermeyer, L Hermle et al.
Clinical evidence suggests that hallucinogenic drug-induced altered states of consciousness (ASCs) and the incipient, acute stages of endogenous psychoses share many common phenomenological features. The aim of our study was to assess hallucinogen-like phenomena in endogenous psychotic patients using standardised methods. We examined 93 endogenous psychotic patients, 50 healthy controls and a...
European psychiatry : the journal of the Association of European Psychiatrists
1996
F Ames, David Castle
In the context of the discovery of the cerebral ligand for the cannabis receptor, and the elucidation of its genetic sequence, we discuss the psychomimetic properties of Cannabis sativa, and explore the relationship between cannabis intoxication and mood. We suggest that renewed study of acute cannabis encephalopathy would be rewarding not only in deepening our understanding of consciousness in...